Clinical Trials Browser

INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × 30 days × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT05316155 2026-04-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

235 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-04-13

Nova-sTAR

Recruiting

150 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06995677 2026-04-09

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-04-07

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07144319 2026-04-01

ENAiBLE

Recruiting

500 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

369 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06810141 2026-03-27

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

POTOMAC

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

SunRISe-5

MoonRISe-1

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Nova-sTAR

SURF302

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

INTerpath-011

ENAiBLE

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer